PROSTVAC™ and the future of prostate cancer
treatment
When the results of the Phase II studies have been confirmed in
a Phase III programme, PROSTVAC™ would have the potential to
significantly extend the lives of people with advanced prostate
cancer.
- Bavarian Nordic is in a strong position to take PROSTVAC™
to its next stage of development, building on its expertise in
research, development and manufacturing of vaccines to progress to
Phase III clinical trials.
